An article published in January 2015 in Diabetes, Obesity and Metabolism explored the pharmacodynamics and the benefits of Dapagliflozin and Canagliflozin in the fight against obesity and type 2 diabetes. This double-blind, randomized study involved both males and females between the ages of 18 and 55. All participants were deemed healthy and free of significant[…]
Can Dapagliflozin and Canagliflozin Fight Type 2 Diabetes and Obesity?
Anti-Diabetic, Drug Research & Development API Tags: DapagliflozinEuropeObesityUnited States Mar 03, 2015
Fluocinolone Acetonide Approved for Diabetic Macular Edema
Anti-Inflammatory, Hormonal Agent, OTC and Compounding Product Tags: Europe Jul 17, 2014
As the leading cause of blindness in the United States Diabetic Macular Edema {DME} is a serious concern for the growing aging population, affecting roughly one million Americans. The recent announcement from pSivida Corp. regarding the marketing authorization in the EU of their DME treatment Fluocinolone is hopeful for U.S. supporters of this formidable drug.[…]
Breaking News: Riociguat FDA Approval Brings Relief
Cardiovascular Agent, Drug Research & Development API Tags: Europehypertension Oct 10, 2013
Riociguat, CAS# 625115-55-1, was approved yesterday by the FDA for the treatment of thromboembolic pulmonary hypertension. Known as the brand name Adempas, Riociguat has proven in trials to be an efficacious treatment option for adults with both persistent and recurrent thromboembolic pulmonary hypertension. The patient population suffering from chronic (CTPH) or recurrent thromboembolic pulmonary hypertension is[…]
Telavancin Gains Expanded-Use Approval by the FDA
Antibiotic Tags: antibioticEuropeMRSA Jul 16, 2013
In late June 2013 Telavancin, also known as the brand name antibiotic Vibativ, was approved by the FDA to treat bacterial pneumonia. Marketed by Theravance, Telavancin is an efficacious antibiotic treatment that has been previously approved in both the United States and Europe for bacterial and skin infections. This new approved indication for Telavancin is[…]
Levodopa Is a Major Player in New Research for Parkinson's Disease
Anti-Parkinsons, Drug Research & Development API, TEVA API Tags: EuropeRestless Legs Syndrome Jun 11, 2012
Levodopa is typically prescribed alongside carbidopa to treat Parkinson’s disease. Brand names Sinemet and Sinemet CR are comprised of levodopa and carbidopa, and systemic levodopa can be found under the names Dopar and Larodopa. Classified as a dopaminergic antiparkinsonism agent, levodopa is also used to treat Periodic Limb Movement Disorder and Restless Legs Syndrome when[…]
Carfilzomib in Development as a Treatment for Multiple Myeloma
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: Europemultiple myeloma Feb 10, 2012
Carfilzomib, CAS number 868540-17-4, is a late-stage, selective next-generation proteasome inhibitor for patients with multiple myeloma. Developed by Onyx, carfilzomib has the ability to irreversibly bind to and inhibit the chymotrypsin-like activity of the 20S proteasome, which is an enzyme that degrades unwanted cellular proteins. The subsequent inhibition of the proteasome-mediated proteolysis creates a build-up[…]
Ancrod present favorable benefit-risk outcomes in ischemic stroke patients
Antithrombotic, Drug Research & Development API Tags: Europe Nov 04, 2011
Stroke is the leading cause of neurologic disability in the US and Europe among adults. Worldwide, it is the second leading cause of death, trailing after coronary artery disease (CAD) in developed nations. In an ischemic stroke, the patient’s blood supply to certain parts of the brain is decreased, resulting to loss of function in[…]
